期刊
PATHOGENS
卷 10, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/pathogens10080927
关键词
Clostridioides difficile infection; 2 ' fucosyl-lactose; lacto-N-neotetraose; human milk oligosaccharides; deoxycholic acid
类别
资金
- DSM Nutritional Products Ltd.
- NOSTRADAMUS project (Eurostars Cut-Off 10) [8404]
The study demonstrates the potential of human milk oligosaccharides (HMOs) in combating Clostridioides difficile infection (CDI) by reducing pathogen levels and enhancing beneficial microbial growth, aiding in the recovery of intestinal dysbiosis and prevention of CDI recurrence after antibiotic therapy.
Clostridioides difficile (formerly Clostridium difficile) infection (CDI) is one of the most common hospital-acquired infections, which is often triggered by a dysbiosed indigenous gut microbiota (e.g., upon antibiotic therapy). Symptoms can be as severe as life-threatening colitis. The current study assessed the antipathogenic potential of human milk oligosaccharides (HMOs), i.e., 2'-Ofucosyllactose (2' FL), lacto-N-neotetraose (LNnT), and a combination thereof (MIX), against C. difficile ATCC 9689 using in vitro gut models that allowed the evaluation of both direct and, upon microbiota modulation, indirect effects. During a first 48 h fecal batch study, dysbiosis and CDI were induced by dilution of the fecal inoculum. For each of the three donors tested, C. difficile levels strongly decreased (with >4 log CFU/mL) upon treatment with 20 FL, LNnT and MIX versus untreated blanks, coinciding with increased acetate/Bifidobacteriaceae levels. Interindividual differences among donors at an intermediate time point suggested that the antimicrobial effect was microbiota-mediated rather than being a direct effect of the HMOs. During a subsequent 11 week study with the Pathogut (TM) model (specific application of the Simulator of the Human Intestinal Microbial Ecosystem (SHIME (R))), dysbiosis and CDI were induced by clindamycin (CLI) treatment. Vancomycin (VNC) treatment cured CDI, but the further dysbiosis of the indigenous microbiota likely contributed to CDI recurrence. Upon co-supplementation with VNC, both 2 ' FL and MIX boosted microbial activity (acetate and to lesser extent propionate/butyrate). Moreover, 2 ' FL avoided CDI recurrence, potentially because of increased secondary bile acid production. Overall, while not elucidating the exact antipathogenic mechanisms-of-action, the current study highlights the potential of HMOs to combat CDI recurrence, help the gut microbial community recover after antibiotic treatment, and hence counteract the adverse effects of antibiotic therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据